296 related articles for article (PubMed ID: 32907837)
21. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
[TBL] [Abstract][Full Text] [Related]
22. The RASopathies: from pathogenetics to therapeutics.
Hebron KE; Hernandez ER; Yohe ME
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35178568
[TBL] [Abstract][Full Text] [Related]
23. [Update on the treatment of RASopathies].
Duat-Rodriguez A; Hernandez-Martin A
Rev Neurol; 2017 May; 64(s03):S13-S17. PubMed ID: 28524213
[TBL] [Abstract][Full Text] [Related]
24. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
Sacco E; Spinelli M; Vanoni M
Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
[TBL] [Abstract][Full Text] [Related]
25. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
Aguilar BJ; Zhou H; Lu Q
Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
[TBL] [Abstract][Full Text] [Related]
26. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
27. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
28. Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.
El-Chaar NN; Piccolo SR; Boucher KM; Cohen AL; Chang JT; Moos PJ; Bild AH
Mol Oncol; 2014 Oct; 8(7):1339-54. PubMed ID: 24908424
[TBL] [Abstract][Full Text] [Related]
29. Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation.
Raepple D; von Lintig F; Zemojtel T; Duchniewicz M; Jung A; Lübbert M; Boss GR; Scheele JS
Ann Hematol; 2009 Apr; 88(4):319-24. PubMed ID: 18784923
[TBL] [Abstract][Full Text] [Related]
30. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
[TBL] [Abstract][Full Text] [Related]
31. Role of farnesyltransferase inhibitors in hematologic malignancies.
Santos ES; Rosenblatt JD; Goodman M
Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
[TBL] [Abstract][Full Text] [Related]
32. Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.
Lo HW
Curr Cancer Drug Targets; 2010 Dec; 10(8):840-8. PubMed ID: 20718706
[TBL] [Abstract][Full Text] [Related]
33. New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications.
Marjanska A; Galazka P; Wysocki M; Styczynski J
Anticancer Res; 2020 Apr; 40(4):1817-1831. PubMed ID: 32234870
[TBL] [Abstract][Full Text] [Related]
34. A brief history of RAS and the RAS Initiative.
McCormick F
Adv Cancer Res; 2022; 153():1-27. PubMed ID: 35101227
[TBL] [Abstract][Full Text] [Related]
35. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
36. The RASopathies.
Rauen KA
Annu Rev Genomics Hum Genet; 2013; 14():355-69. PubMed ID: 23875798
[TBL] [Abstract][Full Text] [Related]
37. RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
[TBL] [Abstract][Full Text] [Related]
38. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.
Guin S; Theodorescu D
Acta Pharmacol Sin; 2015 Mar; 36(3):291-7. PubMed ID: 25557115
[TBL] [Abstract][Full Text] [Related]
39. [Progress of targeted therapy related to K-ras mutation].
Li ZW; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
[No Abstract] [Full Text] [Related]
40. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]